|Opened left ventricle showing thickening, dilatation, and subendocardial fibrosis noticeable as increased whiteness of the inside of the heart.|
|Treatment||Depends on type and symptoms|
|Frequency||2.5 million with myocarditis (2015)|
|Deaths||354,000 with myocarditis (2015)|
Cardiomyopathy is a group of diseases that affect the heart muscle. Early on there may be few or no symptoms. As the disease worsens, shortness of breath, feeling tired, and swelling of the legs may occur, due to the onset of heart failure. An irregular heart beat and fainting may occur. Those affected are at an increased risk of sudden cardiac death.
Types of cardiomyopathy include hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular dysplasia, and Takotsubo cardiomyopathy (broken heart syndrome). In hypertrophic cardiomyopathy the heart muscle enlarges and thickens. In dilated cardiomyopathy the ventricles enlarge and weaken. In restrictive cardiomyopathy the ventricle stiffens.
In many cases, the cause cannot be determined. Hypertrophic cardiomyopathy is usually inherited, whereas dilated cardiomyopathy is inherited in about one third of cases. Dilated cardiomyopathy may also result from alcohol, heavy metals, coronary artery disease, cocaine use, and viral infections. Restrictive cardiomyopathy may be caused by amyloidosis, hemochromatosis, and some cancer treatments. Broken heart syndrome is caused by extreme emotional or physical stress.
Treatment depends on the type of cardiomyopathy and the severity of symptoms. Treatments may include lifestyle changes, medications, or surgery. Surgery may include a ventricular assist device or heart transplant. In 2015 cardiomyopathy and myocarditis affected 2.5 million people. Hypertrophic cardiomyopathy affects about 1 in 500 people while dilated cardiomyopathy affects 1 in 2,500. They resulted in 354,000 deaths up from 294,000 in 1990. Arrhythmogenic right ventricular dysplasia is more common in young people.
Signs and symptoms
Symptoms of cardiomyopathies may include fatigue, swelling of the lower extremities and shortness of breath after exertion. Additional symptoms of the condition may include arrhythmia, fainting, and dizziness.
Cardiomyopathies can be of genetic (familial) or non-genetic (acquired) origin. Genetic cardiomyopathies usually are caused by sarcomere or cytoskeletal diseases, neuromuscular disorders, inborn errors of metabolism, malformation syndromes and sometimes are unidentified. Non-genetic cardiomyopathies can have a definitive causes such as viral infections, myocarditis and others.
Cardiomyopathies are either confined to the heart or are part of a generalized systemic disorder, both often leading to cardiovascular death or progressive heart failure-related disability. Other diseases that cause heart muscle dysfunction are excluded, such as coronary artery disease, hypertension, or abnormalities of the heart valves. Often, the underlying cause remains unknown, but in many cases the cause may be identifiable. Alcoholism, for example, has been identified as a cause of dilated cardiomyopathy, as has drug toxicity, and certain infections (including Hepatitis C). Untreated celiac disease can cause cardiomyopathies, which can completely reverse with a timely diagnosis. In addition to acquired causes, molecular biology and genetics have given rise to the recognition of various genetic causes.
A more clinical categorization of cardiomyopathy as 'hypertrophied', 'dilated', or 'restrictive', has become difficult to maintain because some of the conditions could fulfill more than one of those three categories at any particular stage of their development.
The current American Heart Association (AHA) definition divides cardiomyopathies into primary, which affect the heart alone, and secondary, which are the result of illness affecting other parts of the body. These categories are further broken down into subgroups which incorporate new genetic and molecular biology knowledge.
The pathophysiology of cardiomyopathies is better understood at the cellular level with advances in molecular techniques. Mutant proteins can disturb cardiac function in the contractile apparatus (or mechanosensitive complexes). Cardiomyocyte alterations and their persistent responses at the cellular level cause changes that are correlated with sudden cardiac death and other cardiac problems.
Cardiomyopathies are generally varied individually. Different factors can cause Cardiomyopathies in adults as well as children. To exemplify, Dilated Cardiomyopathy in adults is associated with Ischemic Cardiomyopathy, Hypertension, Valvular diseases, and Genetics. While in Children, Neuromuscular diseases such as Becker muscular dystrophy, including X-linked genetic disorder, are directly linked with their Cardiomyopathies.
thumb|175 px|Normal sinus rhythm on EKG Among the diagnostic procedures done to determine a cardiomyopathy are:
- Physical exam
- Family history
- Blood test
- Stress test
- Genetic testing
Cardiomyopathies can be classified using different criteria:
- Primary/intrinsic cardiomyopathies
- Hypertrophic cardiomyopathy (HCM)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Left ventricular noncompaction
- Ion Channelopathies like the Long QT syndrome and the very rare Short QT syndrome
- Catecholaminergic polymorphic ventricular tachycardia
- Dilated cardiomyopathy (DCM)
- Restrictive cardiomyopathy (RCM)
- Brugada syndrome
- Stress cardiomyopathy
- Myocarditis, inflammation of and injury to heart tissue due in part to its infiltration by lymphocytes and monocytes
- Eosinophilic myocarditis, inflammation of and injury to heart tissue due in part to its infiltration by eosinophils
- Ischemic cardiomyopathy (not formally included in the classification, due to ischemic cardiomyopathy being a direct result of another cardiac problem)
- Secondary/extrinsic cardiomyopathies
- Fabry's disease
- Endomyocardial fibrosis
- Hypereosinophilic syndrome
- Obesity-associated cardiomyopathy
Treatment may include suggestion of lifestyle changes to better manage the condition. Treatment depends on the type of cardiomyopathy and condition of disease, but may include medication (conservative treatment) or iatrogenic/implanted pacemakers for slow heart rates, defibrillators for those prone to fatal heart rhythms, ventricular assist devices (VADs) for severe heart failure, or catheter ablation for recurring dysrhythmias that cannot be eliminated by medication or mechanical cardioversion. The goal of treatment is often symptom relief, and some patients may eventually require a heart transplant.
- Myopathy, a condition affecting skeletal muscles
- Fibrosing cardiomyopathy, a disease in great apes
- Basic Research in Cardiology
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "What Are the Signs and Symptoms of Cardiomyopathy?". 22 June 2016. http://www.nhlbi.nih.gov/health/health-topics/topics/cm/signs.
- ↑ 2.0 2.1 2.2 "Who Is at Risk for Cardiomyopathy?". 22 June 2016. http://www.nhlbi.nih.gov/health/health-topics/topics/cm/atrisk.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Types of Cardiomyopathy". 22 June 2016. http://www.nhlbi.nih.gov/health/health-topics/topics/cm/types.
- ↑ 4.0 4.1 4.2 4.3 4.4 "What Causes Cardiomyopathy?". 22 June 2016. http://www.nhlbi.nih.gov/health/health-topics/topics/cm/causes.
- ↑ 5.0 5.1 5.2 5.3 "How Is Cardiomyopathy Treated?". 22 June 2016. http://www.nhlbi.nih.gov/health/health-topics/topics/cm/treatment.
- ↑ 6.0 6.1 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.". Lancet 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMID 27733282.
- ↑ 7.0 7.1 GBD 2015 Mortality and Causes of Death Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.". Lancet 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMID 27733281.
- ↑ Practical Cardiovascular Pathology. Lippincott Williams & Wilkins. 2010. p. 148. ISBN 9781605478418. https://books.google.com/books?id=ZjaOUqf9LEQC&pg=PA148.
- ↑ GBD 2013 Mortality and Causes of Death Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMID 25530442.
- ↑ 10.0 10.1 10.2 10.3 "What Are the Signs and Symptoms of Cardiomyopathy? - NHLBI, NIH". https://www.nhlbi.nih.gov/health/health-topics/topics/cm/signs.
- ↑ Bakalakos, Athanasios; Ritsatos, Konstantinos; Anastasakis, Aris (2018-09-01). "Current perspectives on the diagnosis and management of dilated cardiomyopathy Beyond heart failure: a Cardiomyopathy Clinic Doctor's point of view" (in en). Hellenic Journal of Cardiology 59 (5): 254–261. doi:10.1016/j.hjc.2018.05.008. ISSN 1109-9666. PMID 29807197.
- ↑ Rath, Anika; Weintraub, Robert (2021-07-23). "Overview of Cardiomyopathies in Childhood". Frontiers in Pediatrics 9: 708732. doi:10.3389/fped.2021.708732. ISSN 2296-2360. PMID 34368032.
- ↑ Gorla, Sudheer; Raja, Kishore; Garg, Ashish; Barbouth, Deborah; Rusconi, Paolo (December 2018). "Infantile Onset Hypertrophic Cardiomyopathy Secondary to PRKAG2 Gene Mutation is Associated with Poor Prognosis" (in en). Journal of Pediatric Genetics 07 (4): 180–184. doi:10.1055/s-0038-1657763. ISSN 2146-4596. PMID 30430036.
- ↑ Law, Michelle L.; Cohen, Houda; Martin, Ashley A.; Angulski, Addeli Bez Batti; Metzger, Joseph M. (February 2020). "Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies" (in en). Journal of Clinical Medicine 9 (2): 520. doi:10.3390/jcm9020520. ISSN 2077-0383. PMID 32075145.
- ↑ Cimiotti, Diana; Budde, Heidi; Hassoun, Roua; Jaquet, Kornelia (2021-01-08). "Genetic Restrictive Cardiomyopathy: Causes and Consequences—An Integrative Approach" (in en). International Journal of Molecular Sciences 22 (2): 558. doi:10.3390/ijms22020558. ISSN 1422-0067. PMID 33429969.
- ↑ Lakdawala, NK; Stevenson, LW; Loscalzo, J (2015). "Chapter 287". Harrison's Principles of Internal Medicine (19th ed.). McGraw-Hill. p. 1553. ISBN 978-0-07-180215-4.
- ↑ Pathophysiology of heart disease : a collaborative project of medical students and faculty. Lilly, Leonard S., Harvard Medical School. (5th ed.). Baltimore, MD: Wolters Kluwer/Lippincott Williams & Wilkins. 2011. ISBN 978-1605477237. OCLC 649701807.
- ↑ "Alcoholic dilated cardiomyopathy.". Nurs Stand 22 (38): 42–7. 2008. doi:10.7748/ns2008.05.22.38.42.c6565. PMID 18578120.
- ↑ 19.0 19.1 "The MOGE(S) classification for cardiomyopathies: current status and future outlook.". Heart Fail Rev 22 (6): 743–752. 2017. doi:10.1007/s10741-017-9641-4. PMID 28721466.
- ↑ Domont F, Cacoub P (2016). "Chronic hepatitis C virus infection, a new cardiovascular risk factor?". Liver Int 36 (5): 621–7. doi:10.1111/liv.13064. PMID 26763484. http://hal.upmc.fr/hal-01274679/document.
- ↑ "Cardiovascular involvement in celiac disease.". World J Cardiol 9 (8): 652–666. 2017. doi:10.4330/wjc.v9.i8.652. PMID 28932354.
- ↑ "Genomic Insights into Cardiomyopathies: A Comparative Cross-Species Review.". Vet Sci 4 (1): 19. 2017. doi:10.3390/vetsci4010019. PMID 29056678.
- ↑ Valentin Fuster; John Willis Hurst (2004). Hurst's the heart. McGraw-Hill Professional. pp. 1884–. ISBN 978-0-07-143225-2. https://books.google.com/books?id=eWQAJDrVV7gC&pg=PA1884. Retrieved 11 November 2010.
- ↑ "Cardiomyopathy Classification: Ongoing Debate in the Genomics Era". Biochem Res Int 2012: 796926. 2012. doi:10.1155/2012/796926. PMID 22924131.
- ↑ Harvey, Pamela A.; Leinwand, Leslie A. (2011-08-08). "Cellular mechanisms of cardiomyopathy". The Journal of Cell Biology 194 (3): 355–365. doi:10.1083/jcb.201101100. ISSN 0021-9525. PMID 21825071.
- ↑ Braunwald, Eugene (2017-09-15). "Cardiomyopathies: An Overview". Circulation Research 121 (7): 711–721. doi:10.1161/CIRCRESAHA.117.311812. ISSN 1524-4571. PMID 28912178.
- ↑ Vinay, Kumar (2013). Robbins Basic Pathology. Elsevier. pp. 396. ISBN 978-1-4377-1781-5.
- ↑ 28.0 28.1 28.2 Maron, Barry J.; Towbin, Jeffrey A.; Thiene, Gaetano; Antzelevitch, Charles; Corrado, Domenico; Arnett, Donna; Moss, Arthur J.; Seidman, Christine E. et al. (11 April 2006). "Contemporary Definitions and Classification of the Cardiomyopathies" (in en). Circulation 113 (14): 1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287. ISSN 0009-7322. PMID 16567565. http://circ.ahajournals.org/content/113/14/1807. Retrieved 1 August 2016.
- ↑ 29.0 29.1 "Eosinophilic cardiac disease: Molecular, clinical and imaging aspects". Archives of Cardiovascular Diseases 108 (4): 258–68. 2015. doi:10.1016/j.acvd.2015.01.006. PMID 25858537.
- ↑ "Viral myocarditis". Current Opinion in Rheumatology 28 (4): 383–9. 2016. doi:10.1097/BOR.0000000000000303. PMID 27166925.
- ↑ Lipshultz, Steven E.; Messiah, Sarah E.; Miller, Tracie L. (2012-04-05). Pediatric Metabolic Syndrome: Comprehensive Clinical Review and Related Health Issues. Springer Science & Business Media. p. 200. ISBN 9781447123651. https://books.google.com/books?id=9GZkyP5NYPwC.
- Boudina, Sihem; Abel, Evan Dale (1 March 2010). "Diabetic cardiomyopathy, causes and effects". Reviews in Endocrine & Metabolic Disorders 11 (1): 31–39. doi:10.1007/s11154-010-9131-7. ISSN 1389-9155. PMID 20180026.
- Marian, A. J.; Roberts, Robert (1 April 2001). "The Molecular Genetic Basis for Hypertrophic Cardiomyopathy". Journal of Molecular and Cellular Cardiology 33 (4): 655–670. doi:10.1006/jmcc.2001.1340. ISSN 0022-2828. PMID 11273720.
- Acton, Q. Ashton (2013). Advances in Heart Research and Application: 2013 Edition. Scholarly Editions. ISBN 978-1-481-68280-0.
- Towbin, JA (2014). "Inherited cardiomyopathies.". Circulation Journal 78 (10): 2347–56. doi:10.1253/circj.cj-14-0893. ISSN 1347-4820. PMID 25186923.
- Maron, Barry J.; Udelson, James E.; Bonow, Robert O.; Nishimura, Rick A.; Ackerman, Michael J.; Estes, N. A. Mark; Cooper, Leslie T.; Link, Mark S. et al. (1 December 2015). "Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology". Circulation 132 (22): e273–280. doi:10.1161/CIR.0000000000000239. ISSN 1524-4539. PMID 26621644.
Original source: https://en.wikipedia.org/wiki/Cardiomyopathy. Read more